Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015.


Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
07 2019
Historique:
received: 03 03 2018
revised: 24 06 2018
accepted: 23 07 2018
pubmed: 15 8 2018
medline: 25 2 2020
entrez: 15 8 2018
Statut: ppublish

Résumé

Kawasaki disease (KD) is an increasingly common vasculitis with risk of coronary artery aneurysms (CAAs). The last UK survey was in 1990, whereas current epidemiology, treatment patterns and complication rates are unknown. The aim of this study was to address this knowledge gap. A British Paediatric Surveillance Unit survey in the UK and Ireland from 1 January 2013 to 28 February 2015 ascertained demographics, ethnicity, seasonal incidence, treatment and complication rates. 553 cases were notified: 389 had complete KD, 46 had atypical KD and 116 had incomplete KD; 2 were diagnosed at postmortem with an incidence of 4.55/100 000 children under 5 years, with a male to female ratio of 1.5:1 and a median age of 2.7 years (2.5 months-15 years). Presentation was highest in January and in rural areas. Most were white (64%), and Chinese and Japanese Asians were over-represented as were black African or African mixed-race children. 94% received intravenous immunoglobulin (IVIG). The overall CAA rate was 19%, and all-cardiac complications affected 28%. Those with CAA received IVIG later than in those without (median 10 days vs 7 days). Those under 1 year had fewer symptoms, but the highest CAA rate (39%). Overall 8 of 512 cases (1.6%) had giant CAA, and 4 of 86 cases (5%) under 1 year of age developed giant CAA. Mortality from KD was 0.36%. The UK and Ireland incidence of KD has increased and is more frequently seen in winter and rural areas. Delayed IVIG treatment is associated with CAA, suggesting earlier and adjunctive primary treatment might reduce complications to prevent CAA, particularly in the very young.

Identifiants

pubmed: 30104394
pii: archdischild-2018-315087
doi: 10.1136/archdischild-2018-315087
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

640-646

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Robert M R Tulloh (RMR)

Paediatric Cardiology, Bristol Royal Hospital for Children, Bristol, UK.
Bristol Medical School, University of Bristol, Bristol, UK.

Richard Mayon-White (R)

Primary Care, University of Oxford, Oxford, UK.

Anthony Harnden (A)

Primary Care, University of Oxford, Oxford, UK.

Athimalaipet V Ramanan (AV)

Paediatric Cardiology, Bristol Royal Hospital for Children, Bristol, UK.
Bristol Medical School, University of Bristol, Bristol, UK.

E Jane Tizard (EJ)

Paediatric Cardiology, Bristol Royal Hospital for Children, Bristol, UK.

Delane Shingadia (D)

Rheumatology, UCL Great Ormond Street Institute of Child Health, London, UK.

Colin A Michie (CA)

Paediatrics, Ealing General Hospital, London, UK.

Richard M Lynn (RM)

British Paediatric Surveillance Unit, Royal College of Paediatrics, London, UK.

Michael Levin (M)

Paediatrics, Imperial College, London, UK.

Orla D Franklin (OD)

Paediatric Cardiology, Our Lady's Children's Hospital, Dublin, Ireland.

Pippa Craggs (P)

Bristol Medical School, University of Bristol, Bristol, UK.

Sue Davidson (S)

Kawasaki Disease Support Group, Coventry, UK.

Rebecca Stirzaker (R)

Social Sciences, Heriot-Watt University, Edinburgh, UK.

Mike Danson (M)

Social Sciences, Heriot-Watt University, Edinburgh, UK.

Paul A Brogan (PA)

Rheumatology, UCL Great Ormond Street Institute of Child Health, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH